AbbVie’s $10.9B Apogee deal strengthens immunology beyond Humira, adds Zumilokibart optionality, and may be undervalued. See ...
Firmus and Sharon AI are trying to keep their distance from one another, but both are becoming increasingly enmeshed in Nvidia’s balance sheet.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results